Akèy › Kansè lestomak › Texas › Houston
Etid klinik pou Kansè lestomak nan Houston, TX
42 etid pou Kansè lestomak ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- UT MD Anderson Cancer Center, Houston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Ap rekriteFaz 2/3
- University of Texas MD Anderson Cancer Center, Houston
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Ap rekriteFaz 2
- Research Site, Houston
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
Ap rekriteFaz 3
- MD Anderson Cancer Center, Houston
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Ap rekriteFaz 2
- Research Site, Houston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson, Houston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Ap rekriteFaz 1
- Baylor College of Medicine, Houston
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Oncology Consultants, Houston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- MD Anderson Cancer Center - University of Texas, Houston
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Ap rekriteFaz 3
- Research Site, Houston
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
Ap rekriteFaz 1
- UT MD Anderson Cancer Center, Houston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site, Houston
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas, MD Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Oncology Consultants, Houston
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Investigative Site #129, Houston
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston
- The University of Texas MD Anderson Cancer Center, Houston
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Ap rekriteFaz 3
- The University of Texas MD Anderson cancer Center, Houston
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Ap rekriteFaz 1
- Baylor St. Luke's Medical Center, Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Houston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Comprehensive Outcomes for After Cancer Health
Ap rekriteVolontè an sante akeyi
- The University of Texas MD Anderson Cancer Center, Houston
- UT Health Houston, Houston
Etid Kansè lestomak nan lòt vil
- Boston, MA32 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Los Angeles, CA22 etid
- Baldwin Park, CA22 etid
- Arlington, VA20 etid
- Dallas, TX19 etid
- San Antonio, TX19 etid
- Grand Rapids, MI18 etid
- St. Louis, MO18 etid
- Washington, DC16 etid
- Detroit, MI16 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)121 etid
- Kansè Metastatik104 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt68 etid
- Kansè pankreyas61 etid
- Melanom59 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.